The human breast cancer resistance protein (BCRP/ABCG2) is an ATP-binding cassette
efflux transporter that uses ATP hydrolysis to expel xenobiotics from cells, including anti …

Since the approval of the first molecularly targeted tyrosine kinase inhibitor (TKI), imatinib, in
2001, TKIs have heralded a new era in the treatment of many cancers. Among their …

Objectives Osimertinib has been reported to be effective against central nervous system
(CNS) metastasis from activating EGFR mutation-positive NSCLC. Nevertheless, the true …

In recent years, more than 50 tyrosine kinase inhibitors (TKIs) was indicated against
numerous cancers, especially outstanding advantages in the treatment of non-small cell …

Cancer treatment is becoming more and more individually based as a result of the large
inter-individual differences that exist in treatment outcome and toxicity when patients are …

Background: advanced-stage non-small cell lung cancer (NSCLC) is characterized by
having limited treatment options and thus a poor prognosis. However, new treatment …

A number of molecularly targeted anticancer drugs that efficiently inhibit receptor tyrosine
kinases, socalled receptor tyrosine kinase inhibitors (TKIs), have been developed. Although …

Pharmacogenomics is an evolving tool of precision medicine. Recently, due to the
introduction of next-generation sequencing and projects generating “Big Data”, a plethora of …

Objective: The aim of the study was to explore the association of pharmacokinetic variability
and pharmacogenomics with the bioequivalence of orally administered gefitinib (Iressa® …

Drug-induced liver injury (DILI) remains a critical clinical issue and has been a treatment
challenge today as it was in the past. However, the traditional biomarkers or indicators are …